Profound Medical Corp.
Profound Medical Corp. (PROF): 2 pipeline candidates · ~20 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
19.6 months
D/E 0.24 · 0% dilution
Lead: Approved
2 candidates
N/A
N/A
A transparent, data-derived signal for Profound Medical Corp.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$244.6M
Cash
$50.3M
Quarterly Burn
$8.6M
Runway
19.6 mo
Revenue
$5.3M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
54
Total value held
$80.7M
| Holder | Shares | Value |
|---|---|---|
| fil ltd | 2,340,000 | $15.2M |
| gagnon securities llc | 1,944,324 | $12.6M |
| royce & associates lp | 1,116,348 | $7.1M |
| letko, brosseau & associates inc | 953,175 | $6.1M |
| mmcap international inc. spc | 745,152 | $4.8M |
| first eagle investment management, llc | 645,414 | $4.2M |
| ardsley advisory partners lp | 575,000 | $3.7M |
| royal bank of canada | 493,060 | $3.2M |
| lagoda investment management, l.p. | 441,015 | $2.9M |
| velan capital investment management lp | 285,710 | $1.9M |
Showing top 10 of 54 institutional holders of Profound Medical Corp.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Profound Medical Corp.'s pipeline?
Profound Medical Corp. (PROF) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Profound Medical Corp.'s lead drug candidate?
Profound Medical Corp.'s most advanced tracked candidate is sonalleve (Approved) for Uterine fibroids, adenomyotic tissue, bone metastases pain, osteoid osteoma, and benign desmoid tumors.
What is Profound Medical Corp.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Profound Medical Corp. has approximately 19.6 months of cash runway.
What is Profound Medical Corp.'s market capitalization?
Profound Medical Corp.'s market capitalization is approximately $244.6M.
Who is the CEO of Profound Medical Corp.?
Dr. Arun Swarup Menawat MBA, Ph.D. is the chief executive officer of Profound Medical Corp. (PROF).
Get the full picture on Profound Medical Corp.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.